Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin
Hussein Abdul Nabi, Luke Dreher, Michael Liu, Soad Al Osta, Suganya A. Karikalan, Eiad Habib, Hicham Z. El Masry · 2026
Read Atrial Fibrillation in Cardiac Amyloidosis: A Multicenter Experience Comparing Novel Oral Anticoagulants and Warfarin by Hussein Abdul Nabi, Luke Dreher, Michael Liu, Soad Al Osta, Suganya A. Karikalan, Eiad Habib, Hicham Z. El Masry (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13300831.txt.
Description
Blood thinners face a stiff test in cardiac amyloidosis, where clots and bleeding both threaten. Hussein Abdul Nabi and colleagues compared warfarin with newer direct oral anticoagulants in a 2026 multicenter review of 422 Mayo Clinic patients who had both amyloidosis and atrial fibrillation. Median follow-up ran 4.3 years.
Twenty-one patients suffered a thromboembolic event. Yearly rates came out low and close, at 0.83 percent on warfarin and 0.67 percent on the newer drugs, a gap without statistical weight. Major bleeding touched 9.9 percent of patients overall, again without a clear winner. Pauses in therapy longer than five days raised clot risk, the sharpest warning in the data.
Catalog record
| CREATOR | Hussein Abdul Nabi, Luke Dreher, Michael Liu, Soad Al Osta, Suganya A. Karikalan, Eiad Habib, Hicham Z. El Masry |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20608 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |